keyword
MENU ▼
Read by QxMD icon Read
search

ACY

keyword
https://www.readbyqxmd.com/read/28628881/photodegradation-and-ecotoxicology-of-acyclovir-in-water-under-uv254-and-uv254-h2o2-processes
#1
Danilo Russo, Antonietta Siciliano, Marco Guida, Emilia Galdiero, Angela Amoresano, Roberto Andreozzi, Nuno M Reis, Gianluca Li Puma, Raffaele Marotta
The photochemical and ecotoxicological fate of acyclovir (ACY) through UV254 direct photolysis and in the presence of hydroxyl radicals (UV254/H2O2 process) were investigated in a microcapillary film (MCF) array photoreactor, which provided ultrarapid and accurate photochemical reaction kinetics. The UVC phototransformation of ACY was found to be unaffected by pH in the range from 4.5 to 8.0 and resembled an apparent autocatalytic reaction. The proposed mechanism included the formation of a photochemical intermediate (ϕACY = (1...
June 7, 2017: Water Research
https://www.readbyqxmd.com/read/28452069/the-hdac6-inhibitor-tubacin-induces-release-of-cd133-extracellular-vesicles-from-cancer-cells
#2
Olivia S Chao, Tim C Chang, Maria A Di Bella, Riccardo Alessandro, Fabio Anzanello, Germana Rappa, Oscar B Goodman, Aurelio Lorico
Tumor-derived extracellular vesicles (EVs) are emerging as an important mode of intercellular communication, capable of transferring biologically active molecules that facilitate the malignant growth and metastatic process. CD133 (Prominin-1), a stem cell marker implicated in tumor initiation, differentiation and resistance to anti-cancer therapy, is reportedly associated with EVs in various types of cancer. However, little is known about the factors that regulate the release of these CD133(+) EVs. Here, we report that the HDAC6 inhibitor tubacin promoted the extracellular release of CD133(+) EVs from human FEMX-I metastatic melanoma and Caco-2 colorectal carcinoma cells, with a concomitant downregulation of intracellular CD133...
April 27, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/28270494/blockade-of-deubiquitylating-enzyme-usp1-inhibits-dna-repair-and-triggers-apoptosis-in-multiple-myeloma-cells
#3
Deepika Sharma Das, Abhishek Das, Arghya Ray, Yan Song, Mehmet K Samur, Nikhil C Munshi, Dharminder Chauhan, Kenneth C Anderson
PURPOSE: The ubiquitin proteasome pathway is a validated therapeutic target in multiple myeloma (MM). Deubiquitylating enzyme USP1 participates in DNA damage response and cellular differentiation pathways. To date, the role of USP1 in MM biology is not defined. In the present study, we investigated the functional significance of USP1 in MM using genetic and biochemical approaches. EXPERIMENTAL DESIGN: To investigate the role of USP1 in myeloma, we utilized USP1 inhibitor SJB3-019A (SJB) for studies in myeloma cell lines and patient MM cells...
March 7, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28267067/hdac6-inhibition-effectively-reverses-chemotherapy-induced-peripheral-neuropathy
#4
Karen Krukowski, Jiacheng Ma, Olga Golonzhka, Geoffroy O Laumet, Tanuja Gutti, John H van Duzer, Ralph Mazitschek, Matthew B Jarpe, Cobi J Heijnen, Annemieke Kavelaars
Chemotherapy-induced peripheral neuropathy is one of the most common dose-limiting side effects of cancer treatment. Currently, there is no Food and Drug Administration-approved treatment available. Histone deacetylase 6 (HDAC6) is a microtubule-associated deacetylase whose function includes regulation of α-tubulin-dependent intracellular mitochondrial transport. Here, we examined the effect of HDAC6 inhibition on established cisplatin-induced peripheral neuropathy. We used a novel HDAC6 inhibitor ACY-1083, which shows 260-fold selectivity towards HDAC6 vs other HDACs...
June 2017: Pain
https://www.readbyqxmd.com/read/28264055/enhancement-of-pomalidomide-anti-tumor-response-with-acy-241-a-selective-hdac6-inhibitor
#5
Brian J North, Ingrid Almeciga-Pinto, David Tamang, Min Yang, Simon S Jones, Steven N Quayle
Thalidomide-based Immunomodulatory Drugs (IMiDs®), including lenalidomide and pomalidomide, are effective therapeutics for multiple myeloma. These agents have been approved with, or are under clinical development with, other targeted therapies including proteasome inhibitors, αCD38 monoclonal antibodies, as well as histone deacetylase (HDAC) inhibitors for combination therapy. HDAC inhibitors broadly targeting Class I and IIb HDACs have shown potent preclinical efficacy but have frequently demonstrated an undesirable safety profile in combination therapy approaches in clinical studies...
2017: PloS One
https://www.readbyqxmd.com/read/28245046/treatment-with-a-selective-histone-deacetylase-6-inhibitor-decreases-lupus-nephritis-in-nzb-w-mice
#6
Miranda D Vieson, Alexander M Gojmerac, Deena Khan, Rujuan Dai, John H van Duzer, Ralph Mazitschek, David L Caudell, Xiaofeng Liao, Xin M Luo, Christopher M Reilly
To date, there are 18 histone deacetylase (HDAC) enzymes, divided into four classes, which alter protein function by removing acetyl groups from lysine residues. Prior studies report that non-selective HDAC inhibitors decrease disease in lupus mouse models. Concern for adverse side effects of non-selective HDAC inhibition supports investigation of selective-HDAC inhibition. We hypothesized that a selective HDAC-6 inhibitor (HDAC6i) will alleviate disease in a mouse model of lupus by increasing acetylation of alpha-tubulin...
February 28, 2017: Histology and Histopathology
https://www.readbyqxmd.com/read/28193016/a-cysteine-specific-fluorescent-switch-for-monitoring-oxidative-stress-and-quantification-of-aminoacylase-1-in-blood-serum
#7
Anila H A, Firoj Ali, Shilpi Kushwaha, Nandaraj Taye, Samit Chattopadhyay, Amitava Das
Reagents that allows detection and monitoring of crucial biomarkers with luminescence ON response have significance in clinical diagnostics. A new coumarin derivative is reported here, which could be used for specific and efficient chemodosimetric detection of cysteine, an important biomarker. The probe is successfully used for studying the biochemical transformation of N-acetylcysteine, a commonly prescribed Cys supplement drug to Cys by aminoacylase-1 (ACY-1), an important and endogenous mammalian enzyme...
December 20, 2016: Analytical Chemistry
https://www.readbyqxmd.com/read/28126569/assessment-of-ionic-liquids-toxicity-through-the-inhibition-of-acylase-i-activity-on-a-microflow-system
#8
Ana M O Azevedo, Sarah A P Pereira, Marieta L C Passos, Susana P F Costa, Paula C A G Pinto, André R T S Araujo, M Lúcia M F S Saraiva
Acylase I (ACY I) plays a role in the detoxication and bioactivation of xenobiotics as well in other physiological functions. In this context, an automated ACY I assay for the evaluation of ionic liquids' (ILs) toxicity was developed. The assay was implemented in a sequential injection analysis (SIA) system and was applied to eight commercially available ILs. The SIA methodology was based on the deacetylation of N-acetyl-l-methionine with production of l-methionine, which was determined using fluorescamine...
April 2017: Chemosphere
https://www.readbyqxmd.com/read/28123988/mechanistic-insights-into-acyclovir-polyethylene-glycol-20000-binary-dispersions
#9
Krishnamoorthy Venkateskumar, Subramani Parasuraman, Raju Gunasunderi, Krishnan Sureshkumar, M Muralidhar Nayak, Syed Adnan Ali Shah, Khoo Kassen, Heng Wei Kai
OBJECTIVE: The objective of this study is to provide a mechanistic insight into solubility enhancement and dissolution of acyclovir (ACY) by polyethylene glycol20000 (PEG20000). MATERIALS AND METHODS: Solid dispersions with differing ratios of drug (ACY) and carrier (PEG20000) were prepared and evaluated by phase solubility, in vitro release studies, kinetic analysis, in situ perfusion, and in vitro permeation studies. Solid state characterization was also done by Powder X-Ray Diffraction (PXRD), Differential Scanning Calorimetry (DSC), Fourier Transform Infrared spectroscopy (FT-IR) analysis and surface morphology was assessed by Polarizing Microscopic Image (PMI) analysis, Scanning Electron Microscopy (SEM), Atomic Force Microscopy (AFM), and Nuclear Magnetic Resonance (NMR) analysis...
October 2016: International Journal of Pharmaceutical Investigation
https://www.readbyqxmd.com/read/28105672/the-advantages-of-cyclic-over-acyclic-carbenes-to-access-isolable-capto-dative-c-centered-radicals
#10
Janell K Mahoney, Rodolphe Jazzar, Guy Royal, David Martin, Guy Bertrand
A cyclic and an acyclic di(amino)carbene as well as a cyclic and an acyclic (alkyl)(amino)carbene cleanly react with benzoyl chloride to give the corresponding adducts 1(+)cyc , 1(+)acy , 2(+)cyc , and 2(+)acy , respectively. The reduction of 1(+)cyc and 2(+)cyc derived from cyclic carbenes affords the corresponding radicals 1cyc and 2cyc that are stable at room temperature. In contrast, radicals 1acy and 2acy , derived from acyclic carbenes, cannot be isolated. It is shown that 1acy is as thermodynamically stabilized as its cyclic counterpart 1cyc , but its instability is the result of β-hydrogens of the nitrogen substituent, along with the enhanced flexibility around C-N bonds, which allow for a H(...
May 2, 2017: Chemistry: a European Journal
https://www.readbyqxmd.com/read/28035401/acy-1215-accelerates-vemurafenib-induced-cell-death-of-braf-mutant-melanoma-cells-via-induction-of-er-stress-and-inhibition-of-erk-activation
#11
Ueihuei Peng, Zhihao Wang, Sa Pei, Yunchao Ou, Pengchao Hu, Wanhong Liu, Jiquan Song
BRAFV600E mutation is found in ~50% of melanoma patients and BRAFV600E kinase activity inhibitor, vemurafenib, has achieved a remarkable clinical response rate. However, most patients treated with vemurafenib eventually develop resistance. Overcoming primary and secondary resistance to selective BRAF inhibitors remains one of the most critically compelling challenges for these patients. HDAC6 has been shown to confer resistance to chemotherapy in several types of cancer. Few studies focused on the role of HDAC6 in vemurafenib resistance...
February 2017: Oncology Reports
https://www.readbyqxmd.com/read/28004342/acyclovir-polyethylene-glycol-6000-binary-dispersions-mechanistic-insights
#12
Krishnamoorthy Venkateskumar, Subramani Parasuraman, Raju Gunasunderi, Krishnan Sureshkumar, M Muralidhar Nayak, Syed Adnan Ali Shah, Khassen Khoo, Heng Wei Kai
The dissolution and subsequent oral bioavailability of acyclovir (ACY) is limited by its poor aqueous solubility. An attempt has been made in this work to provide mechanistic insights into the solubility enhancement and dissolution of ACY by using the water-soluble carrier polyethylene glycol 6000 (PEG6000). Solid dispersions with varying ratios of the drug (ACY) and carrier (PEG6000) were prepared and evaluated by phase solubility, in vitro release studies, kinetic analysis, in situ perfusion, and in vitro permeation studies...
December 21, 2016: AAPS PharmSciTech
https://www.readbyqxmd.com/read/27993968/mechanisms-of-acquired-drug-resistance-to-the-hdac6-selective-inhibitor-ricolinostat-reveals-rational-drug-drug-combination-with-ibrutinib
#13
Jennifer E Amengual, Sathyen A Prabhu, Maximilian Lombardo, Kelly Zullo, Paul M Johannet, Yulissa Gonzalez, Luigi Scotto, Xavier Jirau Serrano, Ying Wei, Jimmy Duong, Renu Nandakumar, Serge Cremers, Akanksha Verma, Olivier Elemento, Owen A O'Connor
Purpose: Pan-class I/II histone deacetylase (HDAC) inhibitors are effective treatments for select lymphomas. Isoform-selective HDAC inhibitors are emerging as potentially more targeted agents. ACY-1215 (ricolinostat) is a first-in-class selective HDAC6 inhibitor. To better understand the discrete function of HDAC6 and its role in lymphoma, we developed a lymphoma cell line resistant to ACY-1215.Experimental Design: The diffuse large B-cell lymphoma cell line OCI-Ly10 was exposed to increasing concentrations of ACY-1215 over an extended period of time, leading to the development of a resistant cell line...
June 15, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27982313/hodgkin-s-lymphoma-evaluation-of-patients-submitted-to-autologous-transplantation-of-hematopoietic-cells-in-the-hematology-service-of-the-hospital-walter-cant%C3%A3-dio-fortaleza-brazil
#14
Fernando Barroso Duarte, Mabel Gomes de Brito Fernandes, Jacques Kaufmann, Karine Sampaio Nunes Barroso, João Paulo de Vasconcelos Leitão, Beatriz Stela Gomes de Souza Pitombeira Araujo, Clara Maria Bastos Eloy da Costa, Acy Teles Quixadá-Medica, Jacqueline de Souza Holanda, Samuel Vasconcelos Landim, Maria Helena Pitombeira
The Autologous HSCT is an important alternative for refractory or recurrent HL patients in terms of survival and improved quality of life. This study analyzes the results of autologous BMT performed in HL patients in the Transplant Unit of the HUWC/ HEMOCE (Fortaleza - CE, Brazil). Fifty-two transplanted patients were studied from January 2009 to October 2015, among them, 30 men and 22 women, mean age of 28.2 years. All of them received GCS-F during the mobilization, in some cases associated with Vinorelbine or Plerixafor, with CD34 collection averaging 4...
October 2016: Revista da Associação Médica Brasileira
https://www.readbyqxmd.com/read/27966587/differential-protein-expression-in-metallothionein-protection-from-depleted-uranium-induced-nephrotoxicity
#15
Yuhui Hao, Jiawei Huang, Cong Liu, Hong Li, Jing Liu, Yiping Zeng, Zhangyou Yang, Rong Li
The purpose of this study was to investigate the underlying mechanism of metallothionein (MT) protection from depleted uranium (DU) using a proteomics approach to search for a DU toxicity-differential protein. MT-/- and MT+/+ mice were administrated with a single dose of DU (10 mg/kg, i.p.) or equal volume of saline. After 4 days, protein changes in kidney tissues were evaluated using a proteomics approach. A total of 13 differentially expressed proteins were identified using two-dimensional electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry...
December 14, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27957719/development-of-improved-hdac6-inhibitors-as-pharmacological-therapy-for-axonal-charcot-marie-tooth-disease
#16
Veronick Benoy, Pieter Vanden Berghe, Matthew Jarpe, Philip Van Damme, Wim Robberecht, Ludo Van Den Bosch
Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy, with an estimated prevalence of 1 in 2500. The degeneration of motor and sensory nerve axons leads to motor and sensory symptoms that progress over time and have an important impact on the daily life of these patients. Currently, there is no curative treatment available. Recently, we identified histone deacetylase 6 (HDAC6), which deacetylates α-tubulin, as a potential therapeutic target in axonal CMT (CMT2). Pharmacological inhibition of the deacetylating function of HDAC6 reversed the motor and sensory deficits in a mouse model for mutant "small heat shock protein B1" (HSPB1)-induced CMT2 at the behavioral and electrophysiological level...
April 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://www.readbyqxmd.com/read/27926524/selective-hdac-inhibition-by-acy-241-enhances-the-activity-of-paclitaxel-in-solid-tumor-models
#17
Pengyu Huang, Ingrid Almeciga-Pinto, Matthew Jarpe, John H van Duzer, Ralph Mazitschek, Min Yang, Simon S Jones, Steven N Quayle
ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242). Like the structurally related drug ACY-1215 (ricolinostat), ACY-241 has the potential for a substantially reduced side effect profile versus current nonselective HDAC inhibitor drug candidates due to reduced potency against Class I HDACs while retaining the potential for anticancer effectiveness. We now show that combination treatment of xenograft models with paclitaxel and either ricolinostat or ACY-241 significantly suppresses solid tumor growth...
January 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/27884726/deacetylase-inhibitors-as-a-novel-modality-in-the-treatment-of-multiple-myeloma
#18
REVIEW
Paul G Richardson, Philippe Moreau, Jacob P Laubach, Michelle E Maglio, Sagar Lonial, Jesus San-Miguel
Deacetylase enzymes remove acetyl groups from histone and nonhistone proteins. Dysregulation of deacetylase activity is a hallmark of malignancy, including multiple myeloma (MM). Deacetylase inhibitors (DACi) cause epigenetic modification and inhibition of the aggresome pathway, resulting in death of MM cells. Panobinostat, a pan-DACi, has shown significant clinical benefit and is the first DACi approved for the treatment of MM. It is approved for use in combination with bortezomib and dexamethasone for the treatment of patients with relapsed or relapsed and refractory MM who have received ≥2 prior regimens including bortezomib and an immunomodulatory drug...
November 21, 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/27646843/ricolinostat-plus-lenalidomide-and-dexamethasone-in-relapsed-or-refractory-multiple-myeloma-a-multicentre-phase-1b-trial
#19
MULTICENTER STUDY
Andrew J Yee, William I Bensinger, Jeffrey G Supko, Peter M Voorhees, Jesus G Berdeja, Paul G Richardson, Edward N Libby, Ellen E Wallace, Nicole E Birrer, Jill N Burke, David L Tamang, Min Yang, Simon S Jones, Catherine A Wheeler, Robert J Markelewicz, Noopur S Raje
BACKGROUND: Histone deacetylase (HDAC) inhibitors are an important new class of therapeutics for treating multiple myeloma. Ricolinostat (ACY-1215) is the first oral selective HDAC6 inhibitor with reduced class I HDAC activity to be studied clinically. Motivated by findings from preclinical studies showing potent synergistic activity with ricolinostat and lenalidomide, our goal was to assess the safety and preliminary activity of the combination of ricolinostat with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma...
November 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27614636/distribution-sources-and-risk-assessment-of-polycyclic-aromatic-hydrocarbons-pahs-in-surface-water-in-industrial-affected-areas-of-the-three-gorges-reservoir-china
#20
Binghui Zheng, Yingqun Ma, Yanwen Qin, Lei Zhang, Yanmin Zhao, Wei Cao, Chenchen Yang, Chaonan Han
Water samples were collected from wastewater treatment plant (WWTP), drain water (DW), major tributaries (MT), and main course of the Yangtze River (MY) in areas of three industrial parks (IPs) in Chongqing city in the Three Gorges Reservoir (TGR). Sixteen EPA priority polycyclic aromatic hydrocarbon (PAH) pollutants were quantified to identify the effects of industrial activities on water quality of the TGR. The results showed that 11 individual PAHs were quantified and 5 PAHs (naphthalene (Nap), acenaphthylene (Acy), benzo[k]fluoranthene (BkF), indeno[1,2,3-cd]pyrene (InP), and benzo[g,h,i]perylene (BgP)) were under detection limits in all of the water samples...
December 2016: Environmental Science and Pollution Research International
keyword
keyword
73682
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"